Daily non-political popular news in brief.

Phase I pharmacokinetic study of ECO-4601, a novel bifunctional targeting agent

A first-in-class, targeted investigational therapy specifically designed to inhibit a single protein that functions only during cell division shows potent activity in a broad range of cancer cell lines, say researchers presenting at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

Read more »

Keywords: phase, pharmacokinetic, study, eco-4601, novel, bifunctional, targeting, agent, eco, 4601

« Previous | Next »

Similar news on "Phase I pharmacokinetic study of ECO-4601, a novel bifunctional targeting agent":

1. 'Trojan Horse' agent halts bone metastasis in mice
   11-15-2006 · EurekAlert!
   A novel vascular targeting agent completely prevented the development of bone tumors in 50 percent of the mice tested in a preclinical study, providing early evidence that it could treat, or thwart, growth of tumors in bone, a common destination for a number of cancers when they start to spread.
   Similar news · Read more »
   
2. Mechanoluminescence event yields novel emissions, reactions
   05-08-2007 · EurekAlert!
   Researchers at the University of Illinois report that a new study of mechanoluminescence revealed extensive atomic and molecular spectral emission not previously seen in a mechanoluminescence event. The findings, which appear online this month in the Journal of the American Chemical Society, also include the first report of gas phase chemical reactions resulting from a mechanoluminescence event.
   Similar news · Read more »
   
3. Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054
   09-25-2007 · EurekAlert!
   New Phase II data presented today suggest that ZD4054, a novel compound in development for the treatment of men with hormone-resistant prostate cancer, could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.1 Patients who received ZD4054 10mg once-daily experienced a 45 percent reduction in the risk of death compared to placebo.
   Similar news · Read more »
   
4. Study shows new strategy for developing antidepressants
   12-08-2007 · EurekAlert!
   Researchers may be able to develop an antidepressant which takes effect almost immediately by directly targeting novel molecules in the brain instead of taking a less direct route, which can lead to longer times for medication to take effect, according to a new study presented at the American College of Neuropsychopharmacology Annual Meeting.
   Similar news · Read more »
   
5. Woods Hole Research Center scientists using remote sensing tools to predict bird species richness
   05-14-2007 · EurekAlert!
   Woods Hole Research Center scientists have taken a novel approach to studying biological diversity by making use of laser remote sensing (lidar). WHRC scientists examined the relationships between bird species richness and habitat metrics derived from lidar data acquired by aircraft. They then explored the efficacy of predicting bird richness and abundance based on these metrics. The first phase of this research focuses on results from study sites in the Patuxent Wildlife Refuge in Maryland.
   Similar news · Read more »
   
6. New therapy effectively treats deep vein thrombosis
   01-29-2008 · EurekAlert!
   A novel treatment for blood clots in the legs appears to be safe and effective, according to a pilot study. The study found that injecting or "lacing" the clot with a fiber-binding thrombolytic agent effectively treats deep vein thrombosis and reduces the risk of subsequent recurrence or bleeding.
   Similar news · Read more »
   
7. Protein therapy may reduce infarct size in heart attack patients
   03-25-2007 · EurekAlert!
   Researchers are searching for new methods and therapies to reduce infarct size and improve blood flow to the heart muscle in patients who experience myocardial infarction (MI), or heart attack. In a study presented today at the American College of Cardiology's Innovation in Intervention: i2 Summit in New Orleans, La., a team from the Duke Clinical Research Institute presented the results from a Phase 1 study evaluating a novel protein kinase C inhibitor.
   Similar news · Read more »
   
8. Novel anti-oxidant and anti-inflammatory agent shows effectiveness on key endpoints in trial
   03-27-2007 · EurekAlert!
   Heart attacks are caused by a build-up and instability of plaque in the coronary arteries, which is often a result of chronic inflammation of the blood vessel walls. A study presented today at the American College of Cardiology's 56th Annual Scientific Session assessed whether adding a novel agent with antioxidant and anti-inflammatory properties to optimal medical therapy would reduce coronary events and death among patients with heart disease.
   Similar news · Read more »
   
9. Phase II study shows combination improves survival of metastatic melanoma patients
   06-03-2007 · EurekAlert!
   Two chemotherapy drugs combined with an agent that prevents the growth of blood vessels significantly delayed the spread of tumors in patients with metastatic melanoma.
   Similar news · Read more »
   
10. CTRC enrolls first patients in Novel Phase II study for sarcoma -- Living virus destroys cancer cell
    07-24-2007 · EurekAlert!
    The Cancer Therapy & Research Center Institute for Drug Development, in collaboration with Oncolytics Biotech Inc., a biotechnology company, has enrolled the first two patients in a new Phase II clinical study for patients with various types of sarcomas that have metastasized to the lung. The novel anti-cancer therapy, REOLYSIN, is a living virus, not a chemotherapy drug, that is toxic to cancer cells but not harmful to normal cells.
    Similar news · Read more »